Role of Neoadjuvant Chemotherapy in the Management of Stage IIIC–IV Ovarian Cancer: Survey Results from the Members of the European Society of Gynecological Oncology
暂无分享,去创建一个
B. van Calster | F. Amant | K. Leunen | I. Vergote | A. van der Zee | Sarah Cornelis | B. Van calster
[1] Christian Marth,et al. 2010 Gynecologic Cancer InterGroup (GCIG) Consensus Statement on Clinical Trials in Ovarian Cancer: Report From the Fourth Ovarian Cancer Consensus Conference , 2011, International Journal of Gynecologic Cancer.
[2] W. Lichtenegger,et al. Primary Versus Interval Debulking Surgery in Advanced Ovarian Cancer: Results From a Systematic Single-Center Analysis , 2010, International Journal of Gynecologic Cancer.
[3] B. Rimel,et al. The role of neoadjuvant chemotherapy in the management of patients with advanced stage ovarian cancer: survey results from members of the Society of Gynecologic Oncologists. , 2010, Gynecologic oncology.
[4] G. Kenter,et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. , 2010, The New England journal of medicine.
[5] I. Vergote,et al. Patterns of care in surgery for ovarian cancer in Europe. , 2010, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[6] S. Kehoe,et al. When Should Surgical Cytoreduction in Advanced Ovarian Cancer Take Place? , 2009, Journal of oncology.
[7] I. Vergote,et al. Surgical program building in advanced ovarian cancer: European perspective. , 2009, Gynecologic oncology.
[8] B. Nam,et al. Does Neoadjuvant Chemotherapy Increase Optimal Cytoreduction Rate in Advanced Ovarian Cancer? Meta-Analysis of 21 Studies , 2009, Annals of Surgical Oncology.
[9] A. Reuss,et al. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials , 2009, Cancer.
[10] I. Vergote,et al. EORTC-GCG process quality indicators for ovarian cancer surgery. , 2009, European journal of cancer.
[11] P. Colombo,et al. Aggressive surgical strategies in advanced ovarian cancer: a monocentric study of 203 stage IIIC and IV patients. , 2009, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[12] Jacobus Pfisterer,et al. Variations in institutional infrastructure, physician specialization and experience, and outcome in ovarian cancer: a systematic review. , 2009, Gynecologic oncology.
[13] I Vergote,et al. Timing of debulking surgery in advanced ovarian cancer , 2008, International Journal of Gynecologic Cancer.
[14] R. Ozols,et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] D. Levine,et al. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? , 2007, Gynecologic oncology.
[16] D. Chi,et al. Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis. , 2006, Gynecologic oncology.
[17] C. Tropé,et al. Primary surgery for ovarian cancer. , 2006, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[18] J. Kurtinaitis,et al. Comparison of adjuvant and neoadjuvant chemotherapy in the management of advanced ovarian cancer: a retrospective study of 574 patients , 2006, BMC Cancer.
[19] D. Atallah,et al. Results of interval debulking surgery compared with primary debulking surgery in advanced stage ovarian cancer. , 2003, Journal of the American College of Surgeons.
[20] M. Johnston,et al. Systematic review of first-line chemotherapy for newly diagnosed postoperative patients with stage II, III, or IV epithelial ovarian cancer. , 2002, Gynecologic oncology.
[21] E. Trimble,et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] N. Spirtos,et al. Procedures required to accomplish complete cytoreduction of ovarian cancer: is there a correlation with "biological aggressiveness" and survival? , 2001, Gynecologic oncology.
[23] P. Schwartz,et al. Neoadjuvant chemotherapy for advanced ovarian cancer: long-term survival. , 1999, Gynecologic oncology.
[24] P. V. van Dam,et al. Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients. , 1998, Gynecologic oncology.
[25] Gary G. Koch,et al. Categorical Data Analysis Using The SAS1 System , 1995 .
[26] S. Orsulic,et al. Ovarian Cancer , 1993, British Journal of Cancer.
[27] A. Jemal,et al. Global cancer statistics , 2011, CA: a cancer journal for clinicians.